Cargando…

Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy

Radium-223 dichloride (Ra-223) is the first bone-targeting agent showing improvement in overall survival in patients with castration-resistant prostate cancer (CRPC) and bone metastases. We aimed to assess feasibility of Ra-223 treatment in patients with metastatic hormone-sensitive prostate cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wenter, Vera, Herlemann, Annika, Fendler, Wolfgang P., Ilhan, Harun, Tirichter, Natalia, Bartenstein, Peter, Stief, Christian G., la Fougère, Christian, Albert, Nathalie L., Rominger, Axel, Gratzke, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546468/ https://www.ncbi.nlm.nih.gov/pubmed/28484088 http://dx.doi.org/10.18632/oncotarget.17311

Ejemplares similares

Salvage lymph node dissection after (68)Ga-PSMA or (18)F-FEC PET/CT for nodal recurrence in prostate cancer patients
por: Herlemann, Annika, et al.
Publicado: (2017)

Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy
por: Schmidt-Hegemann, Nina-Sophie, et al.
Publicado: (2018)

Preliminary experience with dosimetry, response and patient reported outcome after (177)Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer
por: Fendler, Wolfgang P., et al.
Publicado: (2016)

Health-Related Quality of Life following Cytoreductive Radical Prostatectomy in Patients with De-Novo Oligometastatic Prostate Cancer
por: Chaloupka, Michael, et al.
Publicado: (2021)

Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy
por: Rogowski, Paul, et al.
Publicado: (2021)

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
por: Du, Yong, et al.
Publicado: (2017)

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer
por: Cox, Heather, et al.
Publicado: (2015)

Current approaches to incorporation of radium-223 in clinical practice
por: Parker, Chris, et al.
Publicado: (2018)

Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride
por: Lien, Lise Marie E, et al.
Publicado: (2015)

Technical Outcome, Clinical Success, and Complications of Low-Milliampere Computed Tomography Fluoroscopy-Guided Drainage of Lymphoceles Following Radical Prostatectomy with Pelvic Lymph Node Dissection
por: D’Anastasi, Melvin, et al.
Publicado: (2022)

Characterization of Human Papilloma Virus in Prostate Cancer Patients Undergoing Radical Prostatectomy—A Prospective Study of 140 Patients
por: Nellessen, Tobias, et al.
Publicado: (2023)

Radium-223 and concomitant therapies: prospects and prudence
por: Yeku, Oladapo, et al.
Publicado: (2016)

Radium 223 dichloride for prostate cancer treatment
por: Deshayes, Emmanuel, et al.
Publicado: (2017)

Distribution of prostate nodes: a PET/CT-derived anatomic atlas of prostate cancer patients before and after surgical treatment
por: Hegemann, Nina-Sophie, et al.
Publicado: (2016)

Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases?
por: Gayed, Isis, et al.
Publicado: (2018)

Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases
por: Kapoor, Anil, et al.
Publicado: (2019)

Minimizing complications during retropubic radical prostatectomy - is ureteral stenting necessary?
por: Schlenker, B, et al.
Publicado: (2010)

Combined Scintigraphy and Tumor Marker Analysis Predicts Unfavorable Histopathology of Neuroblastic Tumors with High Accuracy
por: Fendler, Wolfgang Peter, et al.
Publicado: (2015)

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
por: Heidenreich, Axel, et al.
Publicado: (2019)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Radium-223 for the treatment of castration-resistant prostate cancer
por: El-Amm, Joelle, et al.
Publicado: (2015)

Chemotherapy following radium‐223 dichloride treatment in ALSYMPCA
por: Sartor, Oliver, et al.
Publicado: (2016)

Imaging and dosimetry for radium-223: the potential for personalized treatment
por: Flux, Glenn D
Publicado: (2017)

Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases
por: Yoshida, Keisuke, et al.
Publicado: (2016)

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
por: Uemura, Hiroji, et al.
Publicado: (2017)

Decreasing undesirable absorbed radiation to the intestine after administration of radium-223 dichloride for treatment of bone metastases
por: Ogawa, Kazuma, et al.
Publicado: (2020)

Patient selection and treatment response assessment in radium-223 therapy
por: Kay, M, et al.
Publicado: (2015)

Radium-223 Treatment in mCRPC Patient with Polycythemia Vera
por: de Angelis, Cristina, et al.
Publicado: (2021)

Ocular complications with the use of radium-223: a case series
por: Bloom, Julie R., et al.
Publicado: (2022)

Radium-223 and bone metastatic disease: still more to learn
por: Sartor, Oliver
Publicado: (2023)

Inhibition of Prostate Smooth Muscle Contraction by Inhibitors of Polo-Like Kinases
por: Hennenberg, Martin, et al.
Publicado: (2018)

Retrospective Toxicological Profiling of Radium-223 Dichloride for the Treatment of Bone Metastases in Prostate Cancer Using Adverse Event Data
por: Soldatos, Theodoros G., et al.
Publicado: (2019)

Analysis of Unusual Adverse Effects After Radium-223 Dichloride  Administration
por: Frantellizzi, Viviana, et al.
Publicado: (2020)

Clinical aspects of mCRPC management in patients treated with radium-223
por: Rizzini, Elisa Lodi, et al.
Publicado: (2020)

Fracture Risk in Men with Metastatic Prostate Cancer Treated With Radium-223
por: Hijab, Adham, et al.
Publicado: (2021)

Occurrence of symptomatic lymphocele after open and robot-assisted radical prostatectomy
por: Magistro, Giuseppe, et al.
Publicado: (2021)

Inhibition of Female and Male Human Detrusor Smooth Muscle Contraction by the Rac Inhibitors EHT1864 and NSC23766
por: Li, Bingsheng, et al.
Publicado: (2020)

Total Tumor Volume on (18)F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with (225)Ac-PSMA-I&T
por: Unterrainer, Lena M., et al.
Publicado: (2022)

PSMA-positive nodal recurrence in prostate cancer: Salvage radiotherapy is superior to salvage lymph node dissection in retrospective analysis
por: Schmidt-Hegemann, Nina-Sophie, et al.
Publicado: (2020)

Utility of F-18 FDG PET/CT for Detection of Bone Marrow Metastases in Prostate Cancer Patients Treated with Radium-223
por: Maruyama, Kaoru, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_av2dng52s6pu81n3vhbo608vv9